← Who reports today · Health Care
MRNA · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 2.1% y/y to $145M, operating margin −562.1% vs −638.7%, net loss $782M (vs net loss $825M a year earlier).
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net product sales | $94 · −17.5% |
| Other revenue | $51 · +82.1% |
| Total revenue | $145 · +2.1% |
| Interest income | $67 · −17.3% |
| Net loss | $782 · −5.2% |
| Cost of sales | $93 · −21.8% |
| Research and development | $651 · −7.0% |
| Selling, general and administrative | $216 · −6.1% |
| Other (expense) income, net | −$19 · vs +$8 |
| Provision for income taxes | $15 |
Verdict: revenue grew 2.1% y/y to $145M, operating margin −562.1% vs −638.7%, net loss $782M (vs net loss $825M a year earlier).
Revenue was $87 million in the U.S. and $58 million in international markets; the FDA had set August 5 as its target (PDUFA) date for a decision on mFLUSIVA, the seasonal influenza vaccine candidate.
Source and notation
Source: Moderna press release, 8-K EX-99.1 of 07/31/2026 (SEC EDGAR). The chart figures were matched against the income statement in the release; revenue and net income match SEC XBRL. Other figures in the text are taken from the release. Loss layout: the Net loss node ($782M) is the total amount by which costs, expenses and taxes exceeded revenue and interest income; it is not a source of funds. The bands show how the chart allocates that total shortfall, and the $67M of interest income, across expense and tax lines; this allocation is a display convention that depends on the order of the lines and is not reported in the statement. In the income statement, interest income of $67M is recorded below the operating loss of $815M and, with other expense of $19M, leads to a loss before income taxes of $767M.
Open as an image: MRNA, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “MRNA Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/mrna/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/mrna/q2-2026"><img src="https://whoreportstoday.com/t/mrna/q2-2026/sankey.png" alt="MRNA Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/mrna/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/mrna/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/mrna/q2-2026">MRNA Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Cost of sales was $93 million, including $41 million of inventory write-downs and $23 million of unutilized manufacturing capacity costs; it decreased 22% year over year.
- Research and development expenses were $651 million, a 7% decrease; SG&A fell 6% to $216 million.
- mRNA-1403, the norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis.
- Operating loss was $815M, a −562.1% margin vs −638.7% a year earlier.
- Diluted EPS was −$1.97 vs −$2.13 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
MRNA — Moderna is a biotechnology company that develops and sells mRNA medicines, including vaccines against COVID-19 (Spikevax, mNEXSPIKE) and RSV (mRESVIA), with a pipeline in influenza, oncology and rare diseases.
Headquarters: Cambridge, Massachusetts.
Heads-up
- a net loss in Q2 2026 ($782 · −5.2%)
Net loss for Q2 2026: $782M. Based on the Q2 2026 report.
The company's report ↗More reports: MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q3 2026 · STE · Q2 FY2027 · SYK · Q3 2026 · TECH · Q1 FY2027 · all reports